Drug toxicity is a long-standing concern of modern medicine 1 , with an annual estimate of 750,000 emergency room visits in the United States resulting from unintentional drug toxicity 2 . The liver is the most frequently affected organ, and its failure can result in mortality 3, 4 . Drug-induced hepatotoxicity is also the single most important cause of both US Food and Drug Administration (FDA) non-approval of drugs and withdrawal of drugs from the market after approval. Reducing hepatotoxicity during drug development may be possible with innovative preclinical hepatotoxicity screening methods 3, [5] [6] [7] . Preclinical interrogation of drug hepatotoxicity may also have added benefits in improving patient safety and therapeutic outcomes 6, 8 .
In the liver, drugs undergo enzymatic biotransformation, which enhances metabolite hydrophilicity and clearance from the body 4, 9, 10 . However, biotransformation can also generate reactive radicals or reactive electrophiles through one-or two-electron oxidation reactions, respectively 10 . Because reactive metabolite formation is necessary for most drug-induced hepatotoxicity, it is highly desirable to identify drug candidates that avoid bioactivation 4, 11, 12 . Reactive metabolites are short-lived and typically have half-lives of less than a second, which precludes their detection in plasma and necessitates in situ detection at their sites of formation 4 . Electrophilic reactive metabolites have been used as a measure of drug hepatotoxicity because of the ease of detecting their covalent binding to endogenous nucleophiles (i.e., protein and glutathione) 4, 10 . However, electrophiles are a poor predictor of the hepatotoxic potential of the parent drug molecule 4 , and do not represent a mechanistic link between the administered drug and toxic outcome 7, 10, 11, 13 .
ROS and RNS may be an alternative, superior biomarker of safety 10, 14, 15 . ROS, including hydrogen peroxide, H 2 O 2 , can be generated directly by oxidative phase I enzymes (for example, cytochrome P450 and peroxidase) during metabolism 10 or indirectly by the reaction of radical drug metabolites with oxygen 10 . RNS such as peroxynitrite, ONOO − , are the result of drug metabolite-induced mitochondrial toxicity caused by disruption of the electron transport chain 10, 14 . Because ROS and RNS have distinct sources of production and biological effects, their simultaneous detection could contribute additional insights into the mechanism of drug-induced hepatotoxicity in vivo.
Methods to detect these radical species even individually have encountered technical challenges, which prevented implementation of these methods for preclinical drug-safety screening 3, 10 . We have previously synthesized semiconducting polymer nanoparticles (SPNs) for imaging deep-tissue tumors 16 and for detecting ROS and RNS in vivo in the context of systemic bacterial infection 17 . Here we combined optical molecular imaging with rationally designed livertargeted SPNs to detect ONOO − and H 2 O 2 simultaneously in the liver of living mice and in real time. We demonstrated this approach to monitor in vivo hepatotoxicity caused by two widely used drugs: the analgesic and anti-pyretic acetaminophen (APAP) and the anti-tuberculosis agent isoniazid (INH) .
RESULTS

Design of CF-SPN and sensing mechanism
We used two matrix polymers and two sensing moieties to engineer two channels of optical detection into the SPN (Fig. 1a) : chemiluminescence for detection of H 2 O 2 , and fluorescence for detection of ONOO − and hypochlorite, − OCl (Fig. 1b) . We incorporated a chemiluminescent substrate into the semiconducting polymer matrix of the SPN, which allowed detection of H 2 O 2 without external light excitation via CRET 18 . FRET from the SPN matrix to an oxidationdegradable fluorophore permitted ratiometric detection of ONOO − upon light excitation of the SPN matrix 19 . CRET and FRET are combined into the SPN and form CRET-FRET-SPN (CF-SPN).
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Current drug-safety assays for hepatotoxicity rely on biomarkers with low predictive power. The production of radical species, specifically reactive oxygen species (ROS) and reactive nitrogen species (RNS), has been proposed as an early unifying event linking the bioactivation of drugs to hepatotoxicity and as a more direct and mechanistic indicator of hepatotoxic potential. Here we present a nanosensor for rapid, real-time in vivo imaging of drug-induced ROS and RNS for direct evaluation of acute hepatotoxicity. By combining fluorescence resonance energy transfer (FRET) and chemiluminescence resonance energy transfer (CRET), our semiconducting polymer-based nanosensor simultaneously and differentially detects RNS and ROS using two optically independent channels. We imaged drug-induced hepatotoxicity and its remediation longitudinally in mice after systemic challenge with acetaminophen or isoniazid. We detected dose-dependent ROS and RNS activity in the liver within minutes of drug challenge, which preceded histological changes, protein nitration and DNA double-strand-break induction.
A r t i c l e s
The matrix comprises the near-infrared (NIR) fluorescent semiconducting polymer poly(2,7-(9,9-dioctylfluorene)-alt-4,7bis(thiophen-2-yl)benzo-2,1,3-thiadiazole) (PFODBT), and a galactosylated graft copolymer of poly(styrene) and poly(ethylene glycol) (PS-g-PEG-Gal) ( Fig. 1a) . PFODBT serves as both the FRET energy donor and the CRET energy acceptor, whereas PS-g-PEG-Gal targets the CF-SPN to the liver by the presentation of PEG and conjugated galactose residues, which bind the asialoglycoprotein receptor expressed on the sinusoidal membrane of hepatocytes 20 . The fluorescence-based sensor is a cyanine dye, 2-(2-(2-(β-carboxyethylthio)-3-(2-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)ethylidene-)-1-cyclohexen-1-yl)-1,3,3-trimetyl-3H-indolium (IR775S), which irreversibly decomposes in the presence of ONOO − and − OCl owing to the oxidative cleavage of its polymethine linkers 17, 19 (Fig.  1a) . FRET occurs in the absence of nitrosative species and the CF-SPN emits at both 680 nm and 820 nm after excitation of PFODBT. In the presence of ONOO − or − OCl, IR775S is irreversibly degraded and FRET is abolished, which resultis in an emission enhancement at 680 nm (Fig. 1b) .
The chemiluminescence-based sensor is a hydrophobic peroxyoxalate, bis-(2,4,5-trichloro-6-(pentyloxycarbonyl)phenyl)oxalate (CPPO), which rapidly and selectively decomposes in the presence of H 2 O 2 to form the high-energy 1,2-dioxetanedione intermediate known to excite nearby dye molecules to emit light 18 . The chemiluminescence of CF-SPNs is activated upon elevated local production of H 2 O 2 , decomposing CPPO to the high-energy 1,2-dioxatanedione that subsequently induces luminescence without external excitation ( Fig. 1a,b) .
In vitro characterization of CF-SPNs
The CF-SPNs had average diameters of ~50 nm, as determined by dynamic light scattering and transmission electron microscopy, and were spherical in shape ( Fig. 1c,d) 
npg
A r t i c l e s CF-SPNs showed the broad absorption of PFODBT (500-600 nm) and a peak at 775 nm corresponding to the ONOO − and − OCl-sensing dye IR775S ( Fig. 2a) . Under excitation at 580 nm, we observed fluorescence from both PFODBT (680 nm) and IR775S (820 nm) ( Fig. 2b) , indicating efficient FRET from the CF-SPN matrix (PFODBT) to IR775S. After adding H 2 O 2 without any external light excitation, we detected luminescence from both PFODBT and IR775S (Fig. 2b) . This result confirmed encapsulation of the H 2 O 2 -sensitive chemiluminescence energy donor CPPO within the CF-SPN, and demonstrated efficient CRET from oxidized CPPO to the PFODBT and IR775S acceptors. We then evaluated the specificity of CF-SPNs toward ROS and RNS under physiological conditions in vitro. We quantified the degradation of IR775S resulting from RNS-mediated methine oxidation by measuring the loss of FRET-induced emission at 820 nm after excitation at 580 nm and treatment of CF-SPNs with a variety of oxidants (Fig. 2c) . The fluorescence response of CF-SPNs was most sensitive to the presence of ONOO − and − OCl. To determine the fluorescence spectral change of CF-SPNs in response to RNS, we added ONOO − in a stepwise manner and measured the progressive loss of emission at 820 nm and concurrent gain in emission at 680 nm (Fig. 2d) . The chemiluminescence response of CF-SPNs to various ROS and RNS, assessed without external light excitation ( Fig. 2e) , demonstrated that CRET was only detected in the presence of H 2 O 2 and that this response linearly corresponded to environmental H 2 O 2 (Fig. 2f) . The fluorescence limit of detection of CF-SPNs was 10 nM in response to ONOO − and − OCl (Fig. 2d ) and the chemiluminescence limit of detection of H 2 O 2 was 5 nM (Fig. 2f) . We observed prolonged generation of luminescence in vitro, with a signal half-life of ~80 min (Supplementary Fig. 1a ). Thus, CF-SPNs exhibit the sensitivity required to detect nanomolar changes in oxidative and nitrosative species generated during pathophysiological conditions in vivo 21 .
We incubated CF-SPNs in undiluted mouse serum at 37 °C, and assessed fluorescence (emission ratio of 680 nm/820 nm) and chemiluminescence over time ( Supplementary Fig. 1b ). There was no 
A r t i c l e s change in the fluorescence ratio during the first 4 h of incubation, but we noted a gradual consumption of CPPO that reached a plateau within 2 h, which indicated that imaging should be done within 1 h of CF-SPN administration. As optical imaging is limited by penetration of light through tissue 22 , the depth of imaging penetration of CF-SPNs is critical for the interrogation of deep, absorbing tissue such as the liver. We assessed the depth of imaging penetration after incubation of CF-SPNs with H 2 O 2 using a tissue-mimicking gel phantom composed of gelatin, hemoglobin and intralipid 23 . By overlaying various thicknesses of gel phantom, we found the penetration of the luminescence signal from CF-SPNs to be at least 2.5 cm of gel depth (Supplementary Fig. 1c ). There was no appreciable loss of total chemiluminescence emission from CF-SPNs upon incubation with H 2 O 2 and various concentrations of ONOO − , which supported the independent detection of H 2 O 2 by CF-SPNs through chemiluminescence imaging (Supplementary Fig. 1d ).
In vivo characterization of CF-SPNs
To assess the extent of selective targeting to the liver by galactose 20 , we compared galactose-conjugated SPNs (Gal-SPNs) to an SPN formulation lacking targeting ligand (PEG-SPNs) and administering them to mice to determine accumulation in several tissues. Upon necropsy, we observed a selective and significant liver accumulation of Gal-SPNs relative to PEG-SPNs, which we confirmed after quantitation of SPN fluorescence (Mann-Whitney U test, P < 0.05; Supplementary  Fig. 2a,b) . We confirmed the hepatocellular uptake of Gal-SPNs by ex vivo confocal microscopy 30 min after intravenous administration of nanosensors ( Supplementary Fig. 2c) .
We assessed the rate of CF-SPN uptake and retention in the liver by measuring the total liver fluorescence intensity (the sum of the emission at 680 nm and 820 nm) over time in mice treated with either saline or a toxic dose of APAP (300 mg/kg; Supplementary Fig. 3a) . The uptake of CF-SPNs was independent of drug treatment, with little change in CF-SPN levels in the liver over the course of imaging (80 min). The confirmation of sensor stability, good imaging depth of penetration ( Supplementary Fig. 1 ), significant hepatic accumulation through galactose-mediated targeting (Mann-Whitney U test, P < 0.05) ( Supplementary Fig. 2 ) and stable nanosensor retention in liver tissues ( Supplementary Fig. 3a ) supports the utility of CF-SPNs for monitoring drug-induced hepatotoxicity in real time.
Because production of − OCl requires myeloperoxidase, which is not expressed in hepatocytes, the fluorescent sensor IR775S in the CF-SPNs likely detects ONOO − alone in models of drug-induced liver toxicity. Thus, CF-SPN fluorescence imaging detects ONOO − (RNS), in contrast to our previous work using IR775S for photoacoustic imaging of edema 24 , which involved both ONOO − and − OCl in its etiology. To account for changes in the fluorescence metric (i.e., percentage difference in emission at 680 nm and 820 nm) owing to CF-SPN accumulation in the liver over time and the nonlinear variation in imaging depth of penetration afforded to light emitted at 680 nm versus 820 nm (refs. 25, 26) , normalization of this metric after drug treatment to that for control mice resulted in the fluorescence index for quantifying drug-induced ONOO − (Online Methods).
One of the challenges of using nanosensors to detect ROS and RNS in vivo is the potential generation of oxidative and nitrosative species by the nanosensors themselves 27, 28 . If CF-SPNs induced the production of substantial amounts of ROS or RNS in the liver, we would expect an elevated baseline activation of CF-SPNs after a prior administration of a dose of Gal-SPNs relative to the saline control. npg However, upon predosing with Gal-SPNs, neither the luminescence intensity nor the fluorescence index indicated any significant production of H 2 O 2 or ONOO − (P > 0.05, generalized linear model repeated measure analysis; Supplementary Fig. 3b,c) .
Longitudinal imaging of APAP hepatotoxicity In vivo
The mechanism of APAP-induced hepatotoxicity is well established and is mainly due to phase I metabolism. An overdose of APAP can result in oxidative and nitrosative stress through the overproduction of ROS and RNS. This results in the consumption of key cellular antioxidants, such as glutathione (GSH), initiating a signaling cascade that results in necrotic cell death 29, 30 . Thus APAP-induced hepatotoxicity serves as an ideal model of liver toxicity with which to validate CF-SPNs. We administered APAP to female nude mice intraperitoneally, anesthetized them and fitted them with tail-vein catheters. We acquired sequential fluorescence and luminescence images immediately after administration of 0.8 mg of CF-SPNs ( Fig. 3) , which occurred 15 min after drug administration. Chemiluminescence images showed a significant enhancement in signal by 18 min after the commencement of imaging with APAP overdose (300 mg/kg) (P < 0.05, generalized linear model repeated measures analysis) but we detected only baseline chemiluminescence after administration of lower drug doses (75 mg/kg and 150 mg/kg) (Fig. 3a) . This threshold dose-type toxicity, i.e., dose independence below a critical toxic dose, is in good agreement with the manifestation of APAP-induced hepatotoxicity in mice 4, 31 . Although the increase in chemiluminescence after APAP overdose was sustained over the time course of imaging ( Fig. 3b) , our previous observation of baseline consumption of CPPO in mouse serum ( Supplementary  Fig. 1b ) prompted us to assess the possibility of extending the H 2 O 2 detection window with the readministration of CF-SPNs (Supplementary Fig. 4) . The readministration of CF-SPNs produced an elevated chemiluminescence signal of ~50% the intensity of the initial CF-SPN injection, as compared to a nominal increase in chemiluminescence in a control mouse. The data suggest that extending the period in which H 2 O 2 can be detected is possible through readministration of CF-SPNs, and that a sizeable decrease in H 2 O 2 production occurs within 60 min of APAP administration.
We observed the same threshold dose-type toxicity noted from the chemiluminescence imaging in the fluorescence channel ( Fig. 3a) , in which we observed an increase in the fluorescence index, correspondingly ONOO − , 53 min after administration of CF-SPN in mice receiving 300 mg/kg APAP. Thus, the increase in generation of ONOO − with APAP overdose occurred later than the generation of H 2 O 2 (Fig. 3c) .
We performed immunohistochemical and histological analysis of liver tissue on mice 45 min and 180 min after treatment with APAP ( Fig. 3d,e and Supplementary Fig. 5 ), and noted no histological changes in liver tissue 45 min after drug challenge at any dose level (Supplementary Fig. 5) . Likewise, we observed no foci positive for nitrosative stress, as measured by immunohistochemistry against protein nitrotyrosyl residues, or DNA fragmentation suggesting hepatocyte cell death, as indicated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), at 45 min (Fig. 3d) . However, 180 min after APAP administration, we observed extensive centrilobular protein nitrotyrosyl and TUNELpositive foci, as well as hepatocellular degeneration characteristic of APAP-induced oncotic necrosis 32 , with the 300 mg/kg dose ( Fig. 3e  and Supplementary Fig. 5 ). We did not observe histological changes to liver tissue with lower doses of APAP, in agreement with a threshold toxic dose between 150 mg/kg and 300 mg/kg as detected by the CF-SPNs.
We compared CF-SPNs to luminol, a blue-emitting chemiluminescent reporter commonly used for H 2 O 2 sensing 33 , after APAP overdose. Luminol did not produce a detectable luminescence signal when administered at an equal dose to that of CPPO encapsulated in CF-SPNs (Supplementary Fig. 6 ). This is likely due to the combination of high local concentration of CPPO in CF-SPNs and the efficiency of CRET to the near infrared-emitting PFODBT, which results in a more sensitive imaging probe spectrally tuned for in vivo deep-tissue imaging. Altogether, these results confirm the utility I 680 npg A r t i c l e s of CF-SPNs to detect early hepatotoxicity in vivo, even before the appearance of histological changes in drug-damaged tissue.
Imaging remediation of hepatoxicity in vivo
The proposed mechanism for APAP bioactivation involves CYP450mediated oxidation to an iminoquinone, N-acetylparaquinonimine (NAPQI), which can bind directly to cellular proteins to induce mitochondrial dysfunction and the production of superoxide (O 2 •− ) and ONOO − or undergo reduction by molecular oxygen to directly form O 2
•− and H 2 O 2 (Fig. 4a) 4, 9, 31 . This pathway can be inhibited by administration of GSH (an antioxidant and nucleophilic scavenger of reactive metabolites (i.e., NAPQI) and ROS-RNS 34 ), 1-aminobenzotriazole (1-ABT; a broad-spectrum suicide inhibitor of CYP450 enzymes 35 ) and trans-1,2-dichloroethylene (t-1,2-DCE; a specific inhibitor of CYP2E1 (ref. 35) , the CYP450 isoform responsible for the majority of phase I metabolism of APAP 31 ). Using CF-SPNs, we observed a reduction of chemiluminescence emission and of the fluorescence index ( Fig. 4b-d ) with all three of these inhibitors, which indicated successful remediation of oxidative and nitrosative stress, respectively. However, there were differences in the magnitude and time course of remediation among the inhibitors. GSH, which has been shown to be superior to N-acetylcysteine as antidote to APAP toxicity in mice 36 , resulted in reduced production of H 2 O 2 and ONOO − relative to that in mice receiving APAP alone but still elevated relative to that in mice receiving either 1-ABT or t-1,2-DCE (Fig. 4c,d) . Additionally, 1-ABT and t-1,2-DCE suppressed ONOO − production to the same extent (Fig. 4d) , but t-1,2-DCE completely prevented H 2 O 2 production, and we observed an intense but shortlived (<20 min after CF-SPN administration) production of H 2 O 2 after 1-ABT treatment (Fig. 4c) .
Longitudinal monitoring of INH hepatotoxicity in vivo
We next tested CF-SPNs for detecting the hepatic oxidative and nitrosative stress caused by another widely used chemotherapy agent, INH (Fig. 5) . INH is associated with hepatotoxicity in 3-13% of patients 37 , but its mechanism is still under debate 38 . It has been suggested that phase II metabolism has a role in INH toxicity, but new evidence implicates direct oxidation of the drug as the cause of covalent protein modifications and cellular damage 38, 39 . We acquired sequential fluorescence and luminescence images 15 min after intraperitoneal INH dosing and immediately after administration of CF-SPNs. Unlike the toxicity observed with APAP ( Fig. 3) , INH exhibited a threshold dose-type production of H 2 O 2 but a dose-dependent enhancement of ONOO − production ( Fig. 5a-c) . Additionally, the kinetics of both oxidative and nitrosative stress differed between APAP and INH, with INH inducing a more short-lived oxidative burst (Fig. 5b) and a more rapidly developed and sustained induction of nitrosative stress (Fig. 5c) . The dose-dependent enhancement of hepatotoxicity detected by CF-SPNs correlated with prospective hepatocyte death, as indicated by cell vacuolization observed upon histological examination of liver tissues (Fig. 5d) . Notably, there was a dose-dependent increase in the severity of liver-cell vacuolization that more closely echoed the dosedependent generation of ONOO − (Fig. 5c) , not the threshold dosetype generation of H 2 O 2 (Fig. 5b) . These results demonstrate the applicability of CF-SPNs to the prodromal, longitudinal and in vivo monitoring of drug-induced hepatic oxidative and nitrosative stress independent of the specific mechanism of drug bioactivation (phase I versus phase II), and not limited to a specific drug class.
DISCUSSION
Drug-induced hepatotoxicity reduces the rate of approval of new chemical entities and has a major role in the withdrawal of approved drugs from the market 3,5-7 . We showed that our nanoparticle is capable of simultaneous and differential dual-analyte sensing using two optical channels inherently free from cross-talk, enabling in vivo and longitudinal detection of drug-induced hepatic oxidative and nitrosative stress. Moreover, the imaging results correlate with histological markers of hepatotoxicity that validate ROS and RNS as prodromal imaging biomarkers for evaluation of drug safety.
Although semiconducting polymers have been widely used in optoelectronic devices 40, 41 , they have many advantages for biomedical imaging, such as large mass extinction coefficients that result in efficient fluorescence 42 , excellent acute and subacute polymer biocompatibility equivalent to that of FDA-approved poly(lactate-co-glycolate) 43 , and excellent photostability, which is of particular importance to in vivo imaging of oxidative and nitrosative species. Both quantum dots and small-molecule fluorophores undergo chemical degradation by ROS and RNS, including H 2 O 2 , ONOO − and − OCl 42 , whereas SPNs are resistant to such oxidative chemical bleaching effects 17, 42 . This characteristic makes SPNs a superior optical reporter for robust imaging of oxidative and nitrosative stress, limiting the loss of FRET or CRET to target analyte sensing instead of nanoparticle core degradation. The unique ability to simultaneously use two optical channels (fluorescence and chemiluminescence) for dual-analyte sensing is achieved by efficient and target-specific FRET and CRET of CF-SPNs. The broad absorption peak of the polymer core from cyan to orange wavelengths provided for efficient CRET from the H 2 O 2 sensor CPPO, and its broad red to NIR emission range facilitated efficient FRET to IR775S in the absence of ONOO − and − OCl. The rapid sensing kinetics and large dynamic range of sensitivity allow CF-SPNs to detect nanomolar to micromolar amounts of ROS and RNS in near-real time, enabling the differentiation of threshold dose-type generation (for example, APAP) from classical dose-response generation (for example, INH) of oxidative and nitrosative stress. Of the few resonance energy transfer-based nanosensors reported previously for in vivo ROS sensing, none would make a suitable alternative to CF-SPNs for hepatotoxicity imaging owing to their dependence on quantum dots 44 , Figure 6 The ability of CF-SPN to differentially and simultaneously detect H 2 O 2 and ONOO − provides mechanistic insights into parent drug bioactivation. The majority of H 2 O 2 is produced after phase I bioactivation, either through uncoupling of enzyme-mediated drug oxidation or through the initiation of redox cycling after oxidation of the parent drug. Strong chemiluminescence from CF-SPN suggests the involvement of phase I bioactivation in the mechanism of drug toxicity. Conversely, the production of ONOO − is associated with mitochondrial toxicity and uncoupling of the mitochondrial electron transport chain by reactive drug metabolites. An increase in the FL index indicates the production the ONOO − , and suggests that drug bioactivation leads to mitochondrial dysfunction. 17, 42 , or because they must be injected locally owing to their large size (>500 nm) 18 . Therefore, CF-SPN has the potential to uniquely remediate current limitations in drug-safety screening and to introduce the concept of molecular imaging as a tool to study toxicology in vivo.
Current methods of hepatotoxicity screening generally use covalent binding to biological molecules as drug-safety biomarkers. These assays, however, have limited predictive power because the extent of observed covalent binding correlates poorly to the hepatotoxic potential of the parent drug 4, 45 . CF-SPN has overcome this limitation by using radical reactive species as safety biomarkers, which have been hypothesized to more closely correlate with toxic outcome 10, 14, 15 . The data presented here support the use of H 2 O 2 and ONOO − as imaging biomarkers for drug-safety evaluation, as (i) only at overdose levels were there signs of oncotic necrosis, protein nitration and DNA fragmentation characteristic of APAP hepatotoxicity, (ii) both H 2 O 2 and ONOO − appear very early in the induction of liver damage and precede even histological signs of toxicity, a necessary requirement of an effective safety biomarker 11 , and (iii) the threshold dose-type centrilobular production of H 2 O 2 and ONOO − after APAP overdose is in good agreement with its well-characterized mechanism of toxicity involving both oxidative and nitrosative stress 4, 31 and parallels the kinetics of mitochondrial protein nitration after APAP overdose described previously 46 . Notably, both the threshold dose-type response and the reduction in chemiluminescence emission after pretreatment with GSH are in good agreement with GSH recovery kinetics in mice. The recovery of GSH levels occurred readily in mice treated with 75 mg/kg and 150 mg/kg of APAP, but this was not observed until 5-6 h after challenge with 300 mg/kg of APAP 47 . In support of this literature, our data suggest that the extent to which APAP metabolism can overwhelm endogenous GSH is a critical parameter in hepatotoxic outcome.
As products of drug metabolism, H 2 O 2 suggests elevated production of oxygen radicals derived directly from phase I oxidation 10, 29 , the reaction of drug metabolites with molecular oxygen 10 , or the production of superoxide anion from uncoupling of the mitochondrial electron transport chain 29 , whereas ONOO − is more indicative of either mitochondrial dysfunction or the formation of drug-derived nitrogen radicals ( Fig. 6) 48, 49 . We demonstrated the value of the twochannel imaging of both oxidative and nitrosative stress provided by CF-SPNs when comparing APAP with INH hepatotoxicity. The generation of both H 2 O 2 and ONOO − after APAP challenge showed a threshold dose-type response and correlated with the observed hepatotoxicity. In contrast, after INH challenge, only ONOO − production showed a classical dose dependent-type response, whereas H 2 O 2 exhibited threshold dose-type dependence. Even though INH challenge resulted in both oxidative and nitrosative stress, the correlation of histological signs of hepatotoxicity (i.e., vacuolization) with RNS but not ROS, suggests a mechanistic role for ONOO − generation and mitochondrial dysfunction in INH hepatotoxicity in vivo. Although the mechanism of INH toxicity remains incompletely characterized 38, 39, 50 , these results are supported by new evidence that implicates mitochondrial impairment after INH bioactivation 50, 51 , and by the potentiation of hepatotoxicity in humans deficient in acetylation capacity 39, 52 .
CF-SPN imaging for in vivo mechanistic studies of drug-induced liver toxicity may allow improvements in drug design that avoid specific pathways of bioactivation and may aid in the selection of remediation strategies for hepatotoxicity. In addition, CF-SPNs may be applied to study the etiology and pathophysiology of an array of other diseases 53 . For example, ROS and RNS have a role in chronic inflammatory diseases 53 , acting as signaling and effector molecules in both the innate and adaptive immune response. ROS have been implicated as the initiators of protein misfolding and as the downstream inducers of cell death in the context of neurodegenerative diseases 54 . Overproduction of ROS and RNS by tumor cells alters tumor metabolism, promotes metastasis and angiogenesis, and fosters drug resistance phenotypes 53, 55 . Thus, detection of ROS and RNS in real time and with high spatial and temporal resolution using CF-SPNs may help uncover mechanisms of ROS and RNS production and action in a broad range of diseases and contribute to the development of new therapeutics.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. and then returned to their cage. Animals were euthanized 180 min after drug treatment, and their livers were resected and placed into buffered formalin for histological examination. A separate set of mice was fasted and treated with drug, and their livers were resected after euthanasia to provide tissues for histological examination 45 min after drug treatment. For inhibitor studies, animals were treated with 200 mg/kg of GSH intravenously 5 min before drug treatment 33 , with 0.2 mg/kg of t-1,2-DCE intraperitoneally 2 h before drug treatment 34 or with 100 mg/kg of 1-ABT intraperitoneally 12 h and 24 h before drug treatment 34 as indicated in previous reports. For the assessment of APAP-induced hepatotoxicity with luminol, mice were treated as described, and injected intravenously with 0.2 mg of luminol in 100 ml of saline adjusted to pH 8.0 with NaHCO 3 . To assess the production of hepatic oxidative or nitrosative stress in vivo after administration of SPN, mice were anesthetized by ketamine-xylazine injection and fitted with tail-vein catheters. Either saline or 0.8 mg of Gal-SPN were then administered intravenously, followed immediately by 0.8 mg of CF-SPN. To determine the biodistribution of Gal-SPN and PEG-SPN, 0.8 mg of nanoparticles were administered intravenously to each mouse, which was euthanized 45 min later. Thigh muscle, lungs, heart, liver, kidneys and spleen were resected, placed onto black paper, and imaged using the IVIS Spectrum system with excitation at 580 ± 10 nm and emission at 680 ± 10 nm.
Histology. All tissues were embedded in paraffin before 10 µm sectioning. Histology samples were stained by hematoxylin and eosin under standard protocols. Immunohistochemistry samples were processed using an antinitrotyrosine primary antibody (A-21285, Life Technologies Inc.) at 1:500 dilution, with color development according to the protocol described in the DAKO LSB+ kit. Endogenous peroxidases were quenched before processing. TUNEL staining was performed according to the manufacturer instructions using the ApopTag Plus Peroxidase In situ Apoptosis Kit (EMD Millipore). All images were acquired using an Olympus IX2-UCB (Olympus America Inc.) inverted fluorescence microscope equipped with a Nuance (CRi Inc.) hyperspectral camera capable of brightfield full-color imaging. Data analysis. Chemiluminescence data was processed using Living Image software (v. 4.3.1, PerkinElmer) for all experiments, in addition to fluorescence data for biodistribution experiments. The investigators were not blinded to the treatment group of the animals before data analysis. For fluorescence ratiometric mapping of liver intensity, image scale bars were normalized, with the scale set to a red color scheme. Fluorescence images without photograph overlay were exported as TIFF, read into Matlab (v. 8.0.0.783, The MathWorks Inc.) where the percentage difference between the fluorescence intensity at 680 nm and 820 nm was mapped for the liver region of interest. In order to plot the fluorescence index (FL index) over time, fluorescence intensities of the liver region of interest were extracted for images acquired with emission at 680 nm and at 820 nm using Living Image software. The intensity values, measured in units of radiance efficiency, were exported to Excel (v.14.3.4, Microsoft Corporation) where the percent difference in emission intensity at 680 nm and 820 nm was calculated. Finally, the FL index was calculated as the ratio of the percent difference of drug treated animals to that of control animals according to equation (1) . (1) (1) npg
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